Humana Inc. (HUM)

Humana is trading near the top of its 52-week range, with the stock up 83.31% over the past year and 46.40% over six months. The move has been driven by earnings beats and a steady run of analyst support, and the price now sits 2.23% below its 52-week high of $456.50. The question for investors is whether the rally can hold as the company's earnings path, which the analysts expect to swing sharply higher next year, comes into focus. CleaRank rates the stock Buy with a score of 78 out of 100, the same rating as Wall Street's consensus. The stock rose 1.88% in the latest session on volume 46.6% above its average. Four analysts reiterated their ratings on November 9, 2026, a week after the November 6 report, when Humana beat the EPS estimate and the shares rose 5.33% in the first session that followed.

Humana has been one of the strongest performers in the healthcare sector over the past year, rising 83.31% and setting a 52-week high of $456.50 along the way. The move has been supported by revenue growth of 26.18% in the latest quarter compared with the same quarter a year earlier, well ahead of the sector median of 8.1%. Earnings have also beaten estimates in seven of the last eight reports. The price now sits above its 50-day SMA of $406.95 and its 200-day SMA of $314.83, with the 50-day average itself 29.26% above the 200-day average.

The most recent report, dated November 6, 2026, showed an adjusted loss of $0.70 per share against an estimate of a $1.00 loss, a beat of 30.00%. The shares rose 5.33% in the first session after that report. Not every beat was rewarded, though: after the July 29, 2026 report, which beat by 8.71%, the stock fell 5.99% in its first session. Of the eight reports on record, four were followed by a higher price in the first session and four by a lower one, so the earnings beat alone has not reliably set the direction of the shares.

The stock trades at a trailing P/E of 43.54, a premium of 36.5% to the sector median of 31.9. Its price-to-sales ratio of 0.35 is far below the sector median of 3.4, which reflects a business with thin margins: the net profit margin is 0.8% and the operating margin 1.82%. Return on equity of 6.74% sits below the sector median of 7.3%, and debt-to-equity is 0.71. The stock's earnings are therefore being valued on a recovery that the analysts expect next year, rather than on current profitability.

Insiders have been buyers rather than sellers. Over the last 18 months there were two open-market purchases worth $1.6M and no insider sales. Analyst ratings have been firm: 16 of 26 analysts rate the stock buy or strong buy, nine rate it hold and one sells. Three months ago 12 of the 26 ratings were buy, so the number of buy ratings has risen.

The base case is that Humana keeps trading above its moving averages while earnings estimates do the work. Analysts expect this year's EPS to shrink 46.5% to $9.17 and next year's to grow 86.5% to $17.10, so the stock's valuation depends on that recovery arriving as forecast. If the company delivers the expected growth in revenue, which analysts forecast at 25.6% this year, the median target of $487.50 offers room above the price. The median target sits 9.2% above the price, and the highest target of $596.00 implies more upside for the most bullish analysts, while the lowest target of $280.00 shows how wide the range of views remains. What would make the picture better is a sustained run of beats like the three in 2026 that were followed by gains, with margins widening from the current thin 1.82% operating margin. What would make it worse is a miss, or a fall back toward the 20-day EMA and 50-day SMA, which would test whether buyers defend the trend. A stock with a P/E of 43.54 against a sector median of 31.9 leaves little room for earnings disappointment.

Support sits first at the 20-day EMA of $421.18, the nearest level below the price, which a pullback would meet first. Below that is the 50-day SMA at $406.95, where the stock would need to hold to keep its intermediate uptrend intact. The 200-day SMA at $314.83 is the longer-term trend line, and the 52-week low of $163.11 marks the bottom of the past year's range. Resistance is the 52-week high of $456.50, the nearest level above the price, which a rise would meet first. A close above that high would mark a new 52-week peak.